On August 21, CSPC PHARMA fell 3.05% in regular trading, trading at HK$9.19 per share, with turnover of HK$175 million.

The decline comes one day after the stock surged over 12% following the release of strong interim results. The company reported H1 revenue of RMB 18.594 billion, up 40.1% year-on-year, with attributable profit of RMB 6.094 billion, surging 139.2%. The previous session also saw a boost from Moderna's personalized mRNA cancer vaccine achieving positive Phase 3 results, given CSPC PHARMA's position as a leading domestic mRNA platform developer.

However, Northbound Capital conducted significant net selling of the stock on the rally day, ranking among the top net-sold names, as overall Northbound flows recorded HK$10.412 billion in net outflows. Short-term profit-taking emerged following the sharp prior-day gains, with institutional capital opting to lock in returns, triggering today's pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)